Studies revealed that O-GlcNAcylation stimulates aggressiveness and resistance of several cancers to chemotherapies and targeted therapies by modulating levels, activity, or subcellular localization of HSP proteins (100) including HSP27 (101–103). The gene discussed is HSP90B2P; the disease is cancer.